Literature DB >> 16697773

Differential gene expression identifies subgroups of renal cell carcinoma.

Keith M Skubitz1, Wolfgang Zimmermann, Wolfgang Zimmerman, Robert Kammerer, Stefan Pambuccian, Amy P N Skubitz.   

Abstract

Clear cell carcinoma of the kidney, the most common subtype of renal cell cancer, displays different biological behavior in different patients. This heterogeneity cannot be recognized by light microscopy. In this study, gene expression in 16 clear cell renal cell carcinoma samples and 17 non-malignant tissue types comprising 539 samples was determined using oligonucleotide microarrays representing approximately 40,000 known genes and ESTs. Differences in gene expression were quantified as the fold change in gene expression between the various sets of samples. A set of genes was identified that was overexpressed in the renal cell carcinoma samples compared with the normal kidney samples. Principle component analysis of the set of renal cell carcinomas using this set of genes overexpressed in renal cell cancer revealed the existence of 2 major subgroups among the renal carcinomas. A series of principle component analyses of the set of renal cell carcinomas using different gene sets composed of genes involved in different metabolic pathways also revealed the same 2 major subgroups of the renal cell cancers. Eisen clustering using the same genes also revealed the same 2 major renal cell cancer subsets. Review of the pathology suggested that these 2 subgroups differed in pathologic grade. Genes differentially expressed between the 2 renal cell cancer subsets were identified. Examination of gene expression in each renal cell cancer subset and the pool of renal cell carcinoma samples compared with that in 17 different normal tissues revealed genes specifically overexpressed in renal cell cancer compared with these normal tissues. The authors conclude that gene expression patterns may be useful in helping to further classify subtypes of renal cell carcinoma that may have clinical significance. In addition, the genes identified as overexpressed in each set of clear cell renal cell carcinomas compared with normal tissues may represent useful targets for therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16697773     DOI: 10.1016/j.lab.2006.04.001

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  18 in total

Review 1.  Renal cell carcinoma deep sequencing: recent developments.

Authors:  Leslie J Farber; Kyle Furge; Bin Tean Teh
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

2.  Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns.

Authors:  A Rose Brannon; Anupama Reddy; Michael Seiler; Alexandra Arreola; Dominic T Moore; Raj S Pruthi; Eric M Wallen; Matthew E Nielsen; Huiqing Liu; Katherine L Nathanson; Börje Ljungberg; Hongjuan Zhao; James D Brooks; Shridar Ganesan; Gyan Bhanot; W Kimryn Rathmell
Journal:  Genes Cancer       Date:  2010-02-01

Review 3.  Basic research in kidney cancer.

Authors:  Egbert Oosterwijk; W Kimryn Rathmell; Kerstin Junker; A Rose Brannon; Frédéric Pouliot; David S Finley; Peter F A Mulders; Ziya Kirkali; Hirotsugo Uemura; Arie Belldegrun
Journal:  Eur Urol       Date:  2011-07-05       Impact factor: 20.096

Review 4.  Renal cell carcinoma: where will the state-of-the-art lead us?

Authors:  A Rose Brannon; W Kimryn Rathmell
Journal:  Curr Oncol Rep       Date:  2010-05       Impact factor: 5.075

5.  Classification models for clear cell renal carcinoma stage progression, based on tumor RNAseq expression trained supervised machine learning algorithms.

Authors:  Zeenia Jagga; Dinesh Gupta
Journal:  BMC Proc       Date:  2014-10-13

6.  Gene expression programs of mouse endothelial cells in kidney development and disease.

Authors:  Eric W Brunskill; S Steven Potter
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

Review 7.  Convergence of biomarkers, bioinformatics and nanotechnology for individualized cancer treatment.

Authors:  John H Phan; Richard A Moffitt; Todd H Stokes; Jian Liu; Andrew N Young; Shuming Nie; May D Wang
Journal:  Trends Biotechnol       Date:  2009-05-04       Impact factor: 19.536

Review 8.  From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma.

Authors:  Androu Arsanious; Georg A Bjarnason; George M Yousef
Journal:  Mol Cancer       Date:  2009-03-17       Impact factor: 27.401

9.  Dysregulation of Zinc Finger Protein 395 Contributes to the Pathogenesis of Chondrosarcoma.

Authors:  Changbao Chen; Hua Zhou; Zhongjun Liu; Xinlong Ma
Journal:  Onco Targets Ther       Date:  2021-06-01       Impact factor: 4.147

10.  The hypoxia-inducible transcription factor ZNF395 is controlled by IĸB kinase-signaling and activates genes involved in the innate immune response and cancer.

Authors:  Darko Jordanovski; Christine Herwartz; Anna Pawlowski; Stefanie Taute; Peter Frommolt; Gertrud Steger
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.